Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) notes that it now has approval from the U.S. Bankruptcy Court for...
INSYS Therapeutics Inc.
To improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.
Biotechnology
1d
5d
1m
6m
1y
Max
INSYS Therapeutics Inc. News
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
12 Jun
Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions
Shares of Insys Therapeutics Inc. shot up 83% in premarket trade Wednesday, after the bankrupt opioid maker said it received interim court approvals for its "First Day" motions related to bankruptcy...
INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S....
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe...
11 Jun
Investors are pinning hopes on this asset again — but beware, says Saxo Bank
Our call of the day, from Saxo Bank’s head of commodity strategy Ole Hansen, cautions investors against getting too excited over this haven asset again too soon.
Costs related to recent federal settlements and other lawsuits have forced the Valley drugmaker to file for bankruptcy protection.
10 Jun
Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more
Yahoo Finance's Adam Shapiro fills you in on the top trending news stories that you need to know.
About INSYS Therapeutics Inc.
The culture of compliance efforts at INSYS is the promotion of ethical behavior by employees and corporate responsibility by the company.
In accordance with our values, the INSYS compliance function supports the development and implementation of practices to facilitate compliance with applicable laws and corporate policy. As importantly, due diligence in preventing and detecting misconduct or non-compliance with laws or regulations is supported by these effective compliance systems.
Our employees are encouraged to report concerns or suspected cases of misconduct without the fear of retaliation. Employees can do this through line managers or through our confidential Compliance Helpline reporting channels. All concerns and allegations are fairly and independently investigated, and disciplinary action, if applicable, is commensurate with the issues presented.
The INSYS Compliance Helpline enables employees to report a concern or receive information or advice anonymously. The Compliance Helpline can be reached by phone or online via the web–reporting tool. Accessible 24 hours a day, 7 days a week, 365 days a year and offered in 70 languages, the Compliance Helpline is operated by specially trained third–party representatives.
Team
Ahmed Elkashef
Vice President of Clinical Development
Steven Meyer
Chairman
Elizabeth Bohlen
Director
Trudy Vanhove
Director
Pierre Lapalme
Director
Rohit Vishnoi
Director
$ 0.29
Market cap:
25.354 M
Symbol:
INSY
Contact info
Phone:
+1 602-910-2627
Address:
444 S Ellis Rd, Chandler, AZ 85224, USA
